Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Comment by palinc2000on Jul 29, 2023 5:00pm
117 Views
Post# 35563376

RE:RE:RE:RE:RE:Review of Marathon

RE:RE:RE:RE:RE:Review of MarathonWhat do Paul and Marathon know ?
1- Amount of liquidity as of yesterday...Over 15 million but under 20 million .... They know the exact amount but we dont know...Is it 18 million  and thus making 15 million minimum relatively safe or is it 16 million which is of course riskier

2- June and July revenues if the CFO is able to figure out sales in real time
3- Current  cash flow projections for the next 3 months based on budgeted sales and expense reductions 
4- Status  of discussions if any with possible partners in Nash and Oncology 
5-Status of discussions if any for the addition of a new product to be commercialized by THTX sales team

What they DONT know!

1-If Phase 1 will deliver positive results 

Conclusion
Execution in sales of products and trajectory and timing of expense reductions are the only life savers in the near term and it would help if the Company was more transparent in the near term and provide updates at least on a monthly basis starting August 31 st




<< Previous
Bullboard Posts
Next >>